IPPA Wegovy^® (semaglutida), solución inyectable de 1 mg/1.5 mL, 2 mg/1.5 mL, 4 mg/3 mL, 6.8 mg/3 mL, 9.6 mg/3 mL. Novo Nordisk México, S.A. de C.V. Reg. No. 006M2023 SSA IV.

Rethink Obesity. Understanding complications/comorbidities of obesity. Novo Nordisk. [Internet]. Junio de 2022. [Consultado el 23 de agosto de 2024]. Disponible en: https://www.rethinkobesity.global/global/en/weight-and-health/obesity-related-complications.html#section1.

Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med 2023;33(3):159-66.

Xiang J, Qin L, Zhong J, Xia N, Liang Y. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway. Diabetes Metab Syndr Obes. 2023 Aug 15;16:2433-2446.

Wilding JP, Batterham RL, Calanna S, Davies M, Van-Gaal LF, Lingvay I, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384(11):989-1002.

Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325(14):1414-25.